A Phase 3 interventional study of Phenobarbital Sodium Injection in Epilepsy, Benign Neonatal, sponsored by NEMA Research, Inc.. Terminated at 8 sites in 2 countries. Open to participants aged 34 Weeks to 44 Weeks. Per ClinicalTrials.gov, last updated 2023-10-26.
Sponsored by NEMA Research, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of the administration of phenobarbital sodium injection in neonates who have suffered from electrographic or electroclinical seizure. As neonatal seizures can have long-term adverse effects, including death, placebo-controlled studies are not appropriate for this population. This study is designed to show intravenous phenobarbital is effective at preventing subsequent seizures by demonstrating greater efficacy at a higher dose compared to a lower dose.
NEMA Research, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 20 mg/kg (first/initial dose) followed by 20 mg/kg (if required).
Drug: Phenobarbital Sodium Injection
Following confirmation of seizure criteria and randomization, subjects will receive Phenobarbital 40 mg/kg (first/initial dose) followed by 10 mg/kg (if required).
Drug: Phenobarbital Sodium Injection
The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
Also known as: Phenobarbital
Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.
Percent of neonates who do not require additional seizure treatment after the first dose of phenobarbital during the first 24 hours after treatment.
Time frame: 24 hours
Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital.
Percent of neonates who do not require additional seizure treatment after 2 hours of the first dose of phenobarbital.
Time frame: 2 hours
Neonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital.
Percent of neonates who do not require additional seizure treatment after the second dose of phenobarbital within the first 24 hours of treatment.
Time frame: 24 hours
Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection.
Number of subject required monitoring of seizure burden over 48 hours following initial administration of the phenobarbital injection.
Time frame: 48 hours
| Milestone | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg |
|---|---|---|
| Started | 3 | 1 |
| Completed | 3 | 1 |
| Not completed | 0 | 0 |
Percent of neonates who do not require additional seizure treatment after the first dose of phenobarbital during the first 24 hours after treatment.
| Participants | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg |
|---|---|---|
| Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital. | 2 | 1 |
Percent of neonates who do not require additional seizure treatment after 2 hours of the first dose of phenobarbital.
| Participants | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg |
|---|---|---|
| Neonates Who do Not Require Additional Seizure Treatment After the First Dose of Phenobarbital. | 2 | 1 |
Percent of neonates who do not require additional seizure treatment after the second dose of phenobarbital within the first 24 hours of treatment.
| Participants | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg |
|---|---|---|
| Neonates Who do Not Require Additional Seizure Treatment After the Second Dose of Phenobarbital. | 1 | 0 |
Number of subject required monitoring of seizure burden over 48 hours following initial administration of the phenobarbital injection.
| Participants | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg |
|---|---|---|
| Seizure Burden Over 48 Hours Following Initial Administration of the Phenobarbital Injection. | 1 | 0 |
Collected over All-Cause Mortality and Serious Adverse Events were assessed up to 30 days following the first treatment, on average 45 days. Other (Not Including Serious) Adverse Events were assessed for up to 24 hours following the first treatment and up to 4 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phenobarbital Sodium Injection 20mg | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) |
| Phenobarbital Sodium Injection 40mg | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Event | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg |
|---|---|---|
| pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 1/3 | 0/1 |
| Age, Categorical(Participants) | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg | Total |
|---|---|---|---|
| <=18 years | 3 | 1 | 4 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg | Total |
|---|---|---|---|
| Female | 1 | 0 | 1 |
| Male | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 3 | 0 | 3 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Phenobarbital Sodium Injection 20mg | Phenobarbital Sodium Injection 40mg | Total |
|---|---|---|---|
| United States | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There is no plan to share IPD.
Ran from Mar 2021 to primary completion in Feb 2023, 22 months.
Results were first posted in Oct 2023, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenobarbital
NEMA Research, Inc.